Navega Tx is a preclinical stage company pursuing a radically different approach to treat chronic pain and tackle the opioid epidemic.
We have developed a patented, non-permanent gene therapy to target pain. Startup Navega Therapeutics is the first to apply a variant of CRISPR (and ZFs) that acts as an epigenetic modulator to treat pain.